231 related articles for article (PubMed ID: 20410528)
21. Addressing intra-tumoral heterogeneity and therapy resistance.
Rybinski B; Yun K
Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
[TBL] [Abstract][Full Text] [Related]
22. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
Strauss J; Figg WD
Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
[TBL] [Abstract][Full Text] [Related]
23. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
Lee AJ; Swanton C
Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
[TBL] [Abstract][Full Text] [Related]
24. Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance.
Stein-O'Brien G; Kagohara LT; Li S; Thakar M; Ranaweera R; Ozawa H; Cheng H; Considine M; Schmitz S; Favorov AV; Danilova LV; Califano JA; Izumchenko E; Gaykalova DA; Chung CH; Fertig EJ
Genome Med; 2018 May; 10(1):37. PubMed ID: 29792227
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers of Bad Biology: Curse or a Blessing?
Banerjee S; Sicklick JK
Ann Surg Oncol; 2019 Feb; 26(2):318-320. PubMed ID: 30539488
[No Abstract] [Full Text] [Related]
26. Intratumoral Heterogeneity: From Diversity Comes Resistance.
Pribluda A; de la Cruz CC; Jackson EL
Clin Cancer Res; 2015 Jul; 21(13):2916-23. PubMed ID: 25838394
[TBL] [Abstract][Full Text] [Related]
27. Stochastic gene expression stabilization as a new therapeutic strategy for cancer.
Capp JP
Bioessays; 2012 Mar; 34(3):170-3. PubMed ID: 22231918
[TBL] [Abstract][Full Text] [Related]
28. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
Kim JJ; Rai R
Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
[TBL] [Abstract][Full Text] [Related]
29. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.
Easwaran H; Tsai HC; Baylin SB
Mol Cell; 2014 Jun; 54(5):716-27. PubMed ID: 24905005
[TBL] [Abstract][Full Text] [Related]
30. Translating epigenetics into an anticancer drug pipeline for solid tumors.
Roukos DH
Expert Rev Med Devices; 2011 Jul; 8(4):409-13. PubMed ID: 21728725
[No Abstract] [Full Text] [Related]
31. Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.
Nijman SMB
Trends Cancer; 2020 Jun; 6(6):454-461. PubMed ID: 32460001
[TBL] [Abstract][Full Text] [Related]
32. Cancer's epigenetic drugs: where are they in the cancer medicines?
Ghasemi S
Pharmacogenomics J; 2020 Jun; 20(3):367-379. PubMed ID: 31819161
[TBL] [Abstract][Full Text] [Related]
33. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
McDermott U; Sharma SV; Dowell L; Greninger P; Montagut C; Lamb J; Archibald H; Raudales R; Tam A; Lee D; Rothenberg SM; Supko JG; Sordella R; Ulkus LE; Iafrate AJ; Maheswaran S; Njauw CN; Tsao H; Drew L; Hanke JH; Ma XJ; Erlander MG; Gray NS; Haber DA; Settleman J
Proc Natl Acad Sci U S A; 2007 Dec; 104(50):19936-41. PubMed ID: 18077425
[TBL] [Abstract][Full Text] [Related]
34. Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment.
Poojan S; Bae SH; Min JW; Lee EY; Song Y; Kim HY; Sim HW; Kang EK; Kim YH; Lee HO; Hong Y; Park WY; Jang H; Hong KM
Exp Mol Med; 2020 Jul; 52(7):1102-1115. PubMed ID: 32661348
[TBL] [Abstract][Full Text] [Related]
35. An in vitro model of tumor heterogeneity resolves genetic, epigenetic, and stochastic sources of cell state variability.
Hayford CE; Tyson DR; Robbins CJ; Frick PL; Quaranta V; Harris LA
PLoS Biol; 2021 Jun; 19(6):e3000797. PubMed ID: 34061819
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.
Angus SP; Zawistowski JS; Johnson GL
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():209-229. PubMed ID: 28934561
[TBL] [Abstract][Full Text] [Related]
37. The impact of non-genetic heterogeneity on cancer cell death.
Inde Z; Dixon SJ
Crit Rev Biochem Mol Biol; 2018 Feb; 53(1):99-114. PubMed ID: 29250983
[TBL] [Abstract][Full Text] [Related]
38. Towards precision oncology in RET-aberrant cancers.
Subbiah V; Roszik J
Cell Cycle; 2017 May; 16(9):813-814. PubMed ID: 28318386
[No Abstract] [Full Text] [Related]
39. PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.
Giardina SF; Valdambrini E; Warren JD; Barany F
Curr Cancer Drug Targets; 2021; 21(4):306-325. PubMed ID: 33535953
[TBL] [Abstract][Full Text] [Related]
40. Big genes are big mutagen targets: a connection to cancerous, spherical cells?
Parry ML; Ramsamooj M; Blanck G
Cancer Lett; 2015 Jan; 356(2 Pt B):479-82. PubMed ID: 25451318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
